Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The NF-κB1 mRNA 3′ untranslated region (3′UTR) is a critical regulatory segment of the messenger RNA encoding the p105 precursor of the NF-κB p50 subunit. This region serves as a hub for post-transcriptional control, containing multiple binding sites for microRNAs (miRNAs) and RNA-binding proteins (RBPs) that dictate mRNA stability and translation efficiency. For instance, miR-9 and miR-506 directly bind to the 3′UTR to suppress NF-κB1 expression, acting as tumor suppressors in various cancers such as ovarian and lung cancer. Conversely, the RBP RIG-I can bind to specific motifs within the 3′UTR to promote translation by recruiting ribosomal proteins, thereby enhancing NF-κB signaling. Dysregulation of this region, through mechanisms like alternative polyadenylation (3′UTR shortening) or altered miRNA expression, is linked to chronic inflammation, autoimmune disorders, and oncogenesis. Therapeutic strategies targeting the NF-κB1 3′UTR include miRNA mimics to downregulate the pathway and antisense oligonucleotides (ASOs) designed to modulate its regulatory interactions or stability.
RNA interference (RNAi) mediated by miRNA mimics to induce mRNA degradation or translational repression; Steric hindrance of regulatory protein binding (e.g., RIG-I) by antisense oligonucleotides; Modulation of alternative polyadenylation (APA) to control mRNA stability and protein output.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nuclear factor kappa B subunit 1 mRNA 3′ untranslated region (NFKB1 mRNA 3′UTR) (NFKB1 3′UTR).